Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Keros Therapeutics Q3 EPS $(0.18) Beats $(1.05) Estimate, Sales $14.262M Beat $3.800M Estimate

Author: Benzinga Newsdesk | November 05, 2025 05:04pm
Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(1.05) by 82.81 percent. This is a 87.23 percent increase over losses of $(1.41) per share from the same period last year. The company reported quarterly sales of $14.262 million which beat the analyst consensus estimate of $3.800 million by 275.32 percent. This is a 3.58K percent increase over sales of $388.000 thousand the same period last year.

Posted In: KROS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist